[go: up one dir, main page]

FR23C1023I2 - Anticorps anti-il-36r - Google Patents

Anticorps anti-il-36r

Info

Publication number
FR23C1023I2
FR23C1023I2 FR23C1023C FR23C1023C FR23C1023I2 FR 23C1023 I2 FR23C1023 I2 FR 23C1023I2 FR 23C1023 C FR23C1023 C FR 23C1023C FR 23C1023 C FR23C1023 C FR 23C1023C FR 23C1023 I2 FR23C1023 I2 FR 23C1023I2
Authority
FR
France
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1023C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47215803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1023(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of FR23C1023I1 publication Critical patent/FR23C1023I1/fr
Application granted granted Critical
Publication of FR23C1023I2 publication Critical patent/FR23C1023I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR23C1023C 2011-11-16 2023-05-31 Anticorps anti-il-36r Active FR23C1023I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161560554P 2011-11-16 2011-11-16
US201261644111P 2012-05-08 2012-05-08
US201261713713P 2012-10-15 2012-10-15
PCT/US2012/064933 WO2013074569A1 (en) 2011-11-16 2012-11-14 Anti il-36r antibodies

Publications (2)

Publication Number Publication Date
FR23C1023I1 FR23C1023I1 (fr) 2023-07-21
FR23C1023I2 true FR23C1023I2 (fr) 2024-03-29

Family

ID=47215803

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1023C Active FR23C1023I2 (fr) 2011-11-16 2023-05-31 Anticorps anti-il-36r

Country Status (39)

Country Link
US (4) US9023995B2 (ko)
EP (2) EP3536710A1 (ko)
JP (3) JP6289375B2 (ko)
KR (3) KR102159109B1 (ko)
CN (5) CN112812183B (ko)
AP (1) AP2014007571A0 (ko)
AR (1) AR089178A1 (ko)
AU (1) AU2012339734B2 (ko)
BR (1) BR112014011594B1 (ko)
CA (1) CA2852994C (ko)
CL (1) CL2014001123A1 (ko)
CO (1) CO7020871A2 (ko)
CY (2) CY1122278T1 (ko)
DK (1) DK2780373T3 (ko)
EA (1) EA031948B1 (ko)
EC (1) ECSP14004976A (ko)
ES (1) ES2755732T3 (ko)
FI (1) FIC20230020I1 (ko)
FR (1) FR23C1023I2 (ko)
HR (1) HRP20191835T1 (ko)
HU (2) HUE047437T2 (ko)
IL (2) IL232100B (ko)
LT (2) LT2780373T (ko)
MX (1) MX347164B (ko)
MY (1) MY195289A (ko)
NL (1) NL301233I2 (ko)
NO (2) NO2023024I1 (ko)
PE (1) PE20142041A1 (ko)
PH (1) PH12014501108B1 (ko)
PL (1) PL2780373T3 (ko)
PT (1) PT2780373T (ko)
RS (1) RS59248B1 (ko)
SG (1) SG11201402283PA (ko)
SI (1) SI2780373T1 (ko)
TW (1) TWI573804B (ko)
UA (1) UA115540C2 (ko)
UY (1) UY34456A (ko)
WO (1) WO2013074569A1 (ko)
ZA (1) ZA201402491B (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3885366A3 (en) 2011-01-14 2021-12-29 The Regents of the University of California Therapeutic antibodies against ror-1 protein and methods for use of same
ES2755732T3 (es) 2011-11-16 2020-04-23 Boehringer Ingelheim Int Anticuerpos anti IL-36R
ME02928B (me) 2012-02-24 2018-04-20 Abbvie Stemcentrx Llc Dll3 modulatori i metode upotrebe
US20150259420A1 (en) * 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
RU2582569C2 (ru) * 2014-07-24 2016-04-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом
SG11201707705UA (en) 2015-04-01 2017-10-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
MX2017013080A (es) 2015-04-15 2018-02-09 Anaptysbio Inc Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
EP3307772B1 (en) * 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Tgf-beta 3 specific antibodies and methods and uses thereof
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
BR112019008861A2 (pt) 2016-11-01 2019-07-09 Anaptysbio Inc anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
SG10201913083SA (en) 2017-01-09 2020-03-30 Tesaro Inc Methods of treating cancer with anti-tim-3 antibodies
EP3601350A1 (en) * 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Anti il-36r antibodies combination therapy
US11207294B2 (en) * 2018-01-08 2021-12-28 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
WO2019177888A1 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
WO2019177883A2 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
BR112020027015A2 (pt) * 2018-07-16 2021-04-06 Regeneron Pharmaceuticals, Inc. Proteína de ligação a antígeno isolada, anticorpo ou fragmento de ligação a antígeno do mesmo, complexo, método para produzir uma proteína de ligação a antígeno, proteína de ligação a antígeno ou cadeia de imunoglobulina, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, composição ou kit, composição farmacêutica, recipiente ou dispositivo de injeção, e, método para tratar ou prevenir doenças
US11589562B2 (en) 2018-07-16 2023-02-28 Regeneran Pharmaceuticals, Inc. Mouse model of DITRA disease and uses thereof
EP3837283B1 (en) 2018-08-16 2024-04-17 Cantargia AB Anti-il1rap antibody compositions
US20210380675A1 (en) * 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
AU2019405782A1 (en) * 2018-12-21 2021-06-17 23Andme, Inc. Anti-IL-36 antibodies and methods of use thereof
TW202037604A (zh) * 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
KR20210137520A (ko) * 2019-03-08 2021-11-17 베링거 인겔하임 인터내셔날 게엠베하 항-il-36r 항체 제형
WO2021112196A1 (ja) * 2019-12-05 2021-06-10 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
EP4153233A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of atopic dermatitis
EP4182022A1 (en) 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
IL299648A (en) * 2020-07-30 2023-03-01 Anaptysbio Inc Anti-interleukin 36 receptor therapy for psoriasis
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
MX2023003723A (es) 2020-09-30 2023-04-24 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico.
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
CN116685605A (zh) 2020-12-17 2023-09-01 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022166977A1 (zh) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
BR112023014103A2 (pt) 2021-03-04 2023-10-10 Boehringer Ingelheim Int Métodos para o tratamento de gpp
WO2022192531A2 (en) 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
BR112023017717A2 (pt) * 2021-05-03 2024-01-09 Boehringer Ingelheim Int Método para produção de espesolimabe
BR112023026429A2 (pt) * 2021-06-18 2024-03-05 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticorpo anti-il-36r isolado ou um fragmento de ligação ao antígeno deste, imunoconjugado ou molécula multiespecífica, composição farmacêutica, método para inibir a transdução de sinal de il-36/il-36r e método para tratar doenças e condições relacionadas mediadas por il-36/il-36r em um sujeito em necessidade
WO2023285362A1 (en) 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
WO2023019232A1 (en) 2021-08-13 2023-02-16 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for the treatment of a fibrotic condition
JP2024537724A (ja) 2021-09-28 2024-10-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 目に見える皮膚発現を有する好中球性皮膚疾患の重症度を評価するためのシステム及び方法
WO2023077091A1 (en) * 2021-10-28 2023-05-04 Abbvie Inc. Anti-amyloid beta antibodies and methods of using the same
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用
TW202502379A (zh) 2023-03-09 2025-01-16 德商百靈佳殷格翰國際股份有限公司 抗il-36r抗體用於治療化膿性汗腺炎（hs）之用途
TW202515606A (zh) 2023-06-09 2025-04-16 德商百靈佳殷格翰國際股份有限公司 用於治療及預防全身型膿疱性乾癬之方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
DK0656789T3 (da) 1992-08-21 1998-08-24 Genentech Inc Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse.
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
DE69836082T2 (de) 1997-08-01 2007-05-10 Schering Corp. Membranproteine aus säugetierzellen; verwandte reagentien
PL357939A1 (en) * 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
EP1627927A3 (en) * 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
JP2006506056A (ja) * 2002-10-03 2006-02-23 ラージ・スケール・バイオロジー・コーポレイション 多量体タンパク質操作
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2618482C (en) * 2005-08-19 2014-10-07 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US8034771B2 (en) * 2006-09-08 2011-10-11 Amgen Inc. IL-1F6 polypeptides
MX2009011500A (es) 2007-04-23 2010-01-29 Schering Corp Anticuerpos anti-mdl-1.
ES2540854T3 (es) 2007-06-29 2015-07-14 Merck Sharp & Dohme Corp. Usos de antagonistas MDL-1
MX2011002153A (es) 2008-08-28 2011-03-29 Wyeth Llc Usos de citocinas de las familias de interleucina-22, interleucina-17 e interleucina-1 en enfermedades autoinmunitarias.
ES2755732T3 (es) 2011-11-16 2020-04-23 Boehringer Ingelheim Int Anticuerpos anti IL-36R
MX2017013080A (es) 2015-04-15 2018-02-09 Anaptysbio Inc Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).

Also Published As

Publication number Publication date
TW201333037A (zh) 2013-08-16
JP6719490B2 (ja) 2020-07-08
CN104080808A (zh) 2014-10-01
PT2780373T (pt) 2019-11-27
CY1122278T1 (el) 2020-11-25
US10550189B2 (en) 2020-02-04
CN112812183A (zh) 2021-05-18
CA2852994C (en) 2023-02-14
CY2023014I1 (el) 2023-11-15
MX347164B (es) 2017-04-18
NL301233I2 (nl) 2023-09-13
CL2014001123A1 (es) 2015-01-23
ECSP14004976A (es) 2015-11-30
AU2012339734B2 (en) 2017-02-16
HRP20191835T1 (hr) 2019-12-27
ES2755732T3 (es) 2020-04-23
CO7020871A2 (es) 2014-08-11
MY195289A (en) 2023-01-12
SG11201402283PA (en) 2014-06-27
US20150203584A1 (en) 2015-07-23
CY2023014I2 (el) 2023-11-15
IL232100B (en) 2020-04-30
KR102038310B1 (ko) 2019-11-01
US20200231684A1 (en) 2020-07-23
EA031948B1 (ru) 2019-03-29
CN118515766A (zh) 2024-08-20
FR23C1023I1 (fr) 2023-07-21
AR089178A1 (es) 2014-08-06
KR20200110476A (ko) 2020-09-23
EA201400579A1 (ru) 2014-10-30
NZ623425A (en) 2015-12-24
CN107007833B (zh) 2020-12-11
NO2025001I1 (no) 2025-01-03
PE20142041A1 (es) 2014-12-18
CN104080808B (zh) 2016-11-16
HUS2300021I1 (hu) 2023-07-28
RS59248B1 (sr) 2019-10-31
SI2780373T1 (sl) 2019-12-31
TWI573804B (zh) 2017-03-11
UA115540C2 (uk) 2017-11-27
NL301233I1 (ko) 2023-06-07
CN107007833A (zh) 2017-08-04
PH12014501108A1 (en) 2014-08-04
LTPA2023518I1 (ko) 2023-06-12
CN118496365A (zh) 2024-08-16
PL2780373T3 (pl) 2020-03-31
JP2015500633A (ja) 2015-01-08
KR102159109B1 (ko) 2020-09-23
NO2023024I1 (no) 2023-05-30
LT2780373T (lt) 2019-09-25
KR20140101738A (ko) 2014-08-20
FIC20230020I1 (fi) 2023-06-01
US20130236471A1 (en) 2013-09-12
EP2780373B1 (en) 2019-08-21
EP3536710A1 (en) 2019-09-11
AP2014007571A0 (en) 2014-04-30
IL272035A (en) 2020-02-27
US20240409648A1 (en) 2024-12-12
WO2013074569A1 (en) 2013-05-23
BR112014011594B1 (pt) 2021-11-09
JP6289375B2 (ja) 2018-03-07
DK2780373T3 (da) 2019-11-04
CN112812183B (zh) 2024-06-11
IL232100A0 (en) 2014-05-28
CA2852994A1 (en) 2013-05-23
AU2012339734A1 (en) 2014-04-24
JP2020156506A (ja) 2020-10-01
MX2014005759A (es) 2014-09-08
EP2780373A1 (en) 2014-09-24
US9023995B2 (en) 2015-05-05
ZA201402491B (en) 2021-09-29
BR112014011594A2 (pt) 2017-07-04
HUE047437T2 (hu) 2020-04-28
JP2018093885A (ja) 2018-06-21
US20170298135A9 (en) 2017-10-19
KR20190122877A (ko) 2019-10-30
PH12014501108B1 (en) 2014-08-04
UY34456A (es) 2013-05-31

Similar Documents

Publication Publication Date Title
FR23C1023I2 (fr) Anticorps anti-il-36r
FR24C1019I2 (fr) Anticorps anti-fcrn
EP2703486A4 (en) ANTI-B7-H3 ANTIBODY
EP2930240A4 (en) ANTI-FOLR1 ANTIBODY
EP2714735A4 (en) SPECIFIC ANTIBODIES OF TGF BETA
EP2530091A4 (en) ANTI-DLL3 ANTIBODY
CR20140127A (es) Anticuerpo anti-abtcr
DK2934584T3 (da) Anti-gdf15-antistoffer
BR112012030311A2 (pt) anticorpo
HRP20181646T1 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
EP2768858A4 (en) ANTIBODIES AGAINST INFLUENZA
HUE036663T2 (hu) Készítmény anti-alfa4béta7 antitesthez
HUE036664T2 (hu) Készítmény anti-alfa4béta7 antitesthez
EP2837685A4 (en) ANTI-FGFR2 ANTIBODY
EP2847231A4 (en) MULTISPECIFIC MONOCLONAL ANTIBODIES
DK3467500T3 (da) Cobinder-understøttede assayfremgangsmåder
DK3275892T3 (da) Præfusions-rsv-f-antigener
PT2720563T (pt) Resumo
CO6801637A2 (es) Formulaciones de anticuerpos
PT2543357T (pt) Resumo
EP2844290A4 (en) NOVEL ANTIBODIES
CO6791565A2 (es) Anticuerpos anti-notch1
PT2661870T (pt) Resumo
DK2828292T3 (da) Jcv-neutraliserende antistoffer
DK2935330T3 (da) Anti-notch3-antistoffer